SeaStar Medical Q1 net loss $5.3M; FDA non-approvable letter for pediatric SCD HDE

SeaStar Medical Holding Corp

2023-Q1 EPS reported -$0.40

Net loss of $5.3M ($0.40/sh) vs $1.0M ($0.14/sh) in Q1 2022; cash $725,000 as of Mar 31, 2023.
FDA issued non-approvable letter for pediatric AKI HDE; 90-120 day plan to resubmit, targeting late 2023 approval.
Adult NEUTRALIZE-AKI trial site activated; first patient enrollment expected soon; topline results expected in 2025.
Closed first $3.3M tranche of $9.8M convertible debt; second tranche $2.2M closed after quarter-end.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

SeaStar Medical Holding Corp reported the three months ended March 31, 2023 results: net income $5.3 million, EPS $0.40 per share.

Period: the three months ended March 31, 2023
Net income: $5.3 million
EPS: $0.40 per share
Result: reported results

Exact text from the filing

The net loss for the first quarter of 2023 was $5.3 million, or $0.40 per share, compared with a net loss of $1.0 million, or $0.14 per s

View on SEC.gov

Browse all earnings releases →

SeaStar Medical Holding Corp filing history →

Source: SEC EDGAR

accession 0001193125-23-146082

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.